Cerebrospinal Fluid Biomarkers for Detection of Alzheimer Disease in Patients with Mild...
Jun 1, 2018 - There is insufficient evidence to support the routine use of cerebrospinal fluid (CSF) biomarkers for the detection of progressive dementias in patients with mild cognitive impairment (MCI). These tests carry the risk of overdiagnosis of dementia and, therefore, overtreatment.
American Family Physician : Cochrane for Clinicians
https://www.aafp.org/afp/2018/0601/p714.html
navigate_before 1 navigate_next